Charles River Laboratories International (NYSE:CRL) Shares Acquired Rep. Julie Johnson

Representative Julie Johnson (D-Texas) recently bought shares of Charles River Laboratories International, Inc. (NYSE:CRL). In a filing disclosed on February 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Charles River Laboratories International stock on January 15th. The trade occurred in the Representative’s “MERRILL LYNCH TAX EFFICIENT CORE” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Dell Technologies (NYSE:DELL) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of ALLETE (NYSE:ALE) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 1/27/2025.
• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 1/24/2025.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 1/24/2025.
• Sold $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 1/24/2025.
• Sold $1,001 – $15,000 in shares of Morgan Stanley (NYSE:MS) on 1/24/2025.
• Purchased $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 1/17/2025.

Charles River Laboratories International Stock Down 0.7 %

Charles River Laboratories International stock opened at $152.07 on Friday. The firm has a market cap of $7.78 billion, a price-to-earnings ratio of 19.03, a P/E/G ratio of 6.47 and a beta of 1.37. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $275.00. The firm has a fifty day moving average price of $176.43 and a two-hundred day moving average price of $191.11.

Analyst Upgrades and Downgrades

CRL has been the subject of several research analyst reports. TD Cowen boosted their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Bank of America cut their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. The Goldman Sachs Group cut their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research report on Monday, February 3rd. Finally, Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $200.79.

Institutional Trading of Charles River Laboratories International

Institutional investors have recently bought and sold shares of the stock. Versant Capital Management Inc boosted its stake in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares in the last quarter. Wolff Wiese Magana LLC acquired a new position in Charles River Laboratories International during the 3rd quarter worth about $32,000. Pinnacle Bancorp Inc. lifted its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares in the last quarter. Assetmark Inc. lifted its position in Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares in the last quarter. Finally, Optiver Holding B.V. acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth approximately $37,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).